Considering that sustained activation of ATF6 is exclusively observed in GIST and that the ATF6-HSP90 axis plays a crucial role in MT-KIT stabilization, we propose that ATF6 is a promising multi-effect target for GIST treatment, at least for imatinib-resistant patients with no other therapeutic options. This evidence concerns the gene ATF6 and gastrointestinal stromal tumor.